WO2008009858A3 - Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents
Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée Download PDFInfo
- Publication number
- WO2008009858A3 WO2008009858A3 PCT/FR2007/051685 FR2007051685W WO2008009858A3 WO 2008009858 A3 WO2008009858 A3 WO 2008009858A3 FR 2007051685 W FR2007051685 W FR 2007051685W WO 2008009858 A3 WO2008009858 A3 WO 2008009858A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acne
- treatment
- elovl5
- hyperseborrhoea
- modulators
- Prior art date
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract 3
- 206010000496 acne Diseases 0.000 title abstract 3
- 101150022456 ELOVL5 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100032052 Elongation of very long chain fatty acids protein 5 Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 101000921361 Homo sapiens Elongation of very long chain fatty acids protein 5 Proteins 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité de ELOVL5 ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07823604A EP2046979A2 (fr) | 2006-07-19 | 2007-07-18 | Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée |
CA002656891A CA2656891A1 (fr) | 2006-07-19 | 2007-07-18 | Modulateurs de elovl5 dans le traitement de l'acne ou de l'hyperseborrhee |
US12/320,167 US20090298074A1 (en) | 2006-07-19 | 2009-01-21 | Modulators of ELOVL5 for treating acne or hyperseborrhea |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0653032 | 2006-07-19 | ||
FR0653032A FR2903998B1 (fr) | 2006-07-19 | 2006-07-19 | Modulateurs de elovl5 dans le traitement de l'acne ou de l'hyperseborrhee |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/320,167 Continuation US20090298074A1 (en) | 2006-07-19 | 2009-01-21 | Modulators of ELOVL5 for treating acne or hyperseborrhea |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008009858A2 WO2008009858A2 (fr) | 2008-01-24 |
WO2008009858A9 WO2008009858A9 (fr) | 2008-03-27 |
WO2008009858A3 true WO2008009858A3 (fr) | 2008-05-08 |
Family
ID=37726853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/051685 WO2008009858A2 (fr) | 2006-07-19 | 2007-07-18 | Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090298074A1 (fr) |
EP (1) | EP2046979A2 (fr) |
CA (1) | CA2656891A1 (fr) |
FR (1) | FR2903998B1 (fr) |
WO (1) | WO2008009858A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2938334A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de l'adfp dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
FR2938340A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la carnitine octanoyltransferase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000070945A2 (fr) * | 1999-05-20 | 2000-11-30 | Karolinska Innovations Ab | Genes impliques dans l'allongement des chaines d'acides gras et utilisations associees |
WO2004053094A2 (fr) * | 2002-12-06 | 2004-06-24 | Ppd Development, Lp | Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains |
WO2005030985A2 (fr) * | 2003-09-25 | 2005-04-07 | Devgen N.V. | Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques |
-
2006
- 2006-07-19 FR FR0653032A patent/FR2903998B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-18 CA CA002656891A patent/CA2656891A1/fr not_active Abandoned
- 2007-07-18 WO PCT/FR2007/051685 patent/WO2008009858A2/fr active Application Filing
- 2007-07-18 EP EP07823604A patent/EP2046979A2/fr not_active Withdrawn
-
2009
- 2009-01-21 US US12/320,167 patent/US20090298074A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000070945A2 (fr) * | 1999-05-20 | 2000-11-30 | Karolinska Innovations Ab | Genes impliques dans l'allongement des chaines d'acides gras et utilisations associees |
WO2004053094A2 (fr) * | 2002-12-06 | 2004-06-24 | Ppd Development, Lp | Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains |
WO2005030985A2 (fr) * | 2003-09-25 | 2005-04-07 | Devgen N.V. | Utilisation de sequences d'acides amines impliquees dans l'elongation d'acides gras lors de l'identification et/ou du developpement de composes destines a prevenir et/ou a traiter des maladies metaboliques |
Non-Patent Citations (1)
Title |
---|
JAKOBSSON A. ET AL.: "Fatty acid elongases in mammals: Their regulation and roles in metabolism.", PROGR. LIPID RES., vol. 45, no. 3, May 2006 (2006-05-01), pages 237 - 249, XP005399132, ISSN: 0163-7827 * |
Also Published As
Publication number | Publication date |
---|---|
US20090298074A1 (en) | 2009-12-03 |
FR2903998B1 (fr) | 2008-09-05 |
WO2008009858A2 (fr) | 2008-01-24 |
EP2046979A2 (fr) | 2009-04-15 |
FR2903998A1 (fr) | 2008-01-25 |
WO2008009858A9 (fr) | 2008-03-27 |
CA2656891A1 (fr) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008115518A3 (fr) | Biomarqueurs de l'activité sirtuine et procédés d'utilisation de ceux-ci | |
WO2012040499A3 (fr) | Inhibiteurs métaboliques | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
MX2009007023A (es) | Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos. | |
WO2009124330A3 (fr) | Traitement de maladies tumorales | |
WO2010021693A3 (fr) | Modulateurs de mif | |
MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
WO2007123722A3 (fr) | Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse | |
WO2008009856A3 (fr) | Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée | |
TW200833688A (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
WO2008009855A3 (fr) | Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée | |
WO2007101063A3 (fr) | Traitement de troubles liés au développement | |
WO2008009859A3 (fr) | Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée | |
WO2008115710A3 (fr) | Biomarqueurs pour le cancer | |
WO2008009857A3 (fr) | Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation | |
WO2009017719A8 (fr) | Modulateurs du récepteur ccr9 et leurs procédés d'utilisation | |
WO2008009854A3 (fr) | Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée | |
WO2007002131A3 (fr) | Galk1s modificateurs de la voie pten/akt et methodes d'utilisation | |
WO2008009858A3 (fr) | Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée | |
WO2007083287A3 (fr) | Procédé d'essai permettant d'évaluer l'irritation de la peau | |
WO2008026008A8 (fr) | Protéine | |
WO2007118073A3 (fr) | Obésité et distribution de graisse corporelle | |
WO2006009950A3 (fr) | Genes aldo utilises comme modificateurs de la voie igf et procedes d'utilisation | |
WO2008009852A3 (fr) | Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée | |
WO2008070552A3 (fr) | Inhibiteurs de la protéine tyrosine phosphatase permettant de favoriser l'hypertrophie cardiaque physiologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07823604 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007823604 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2656891 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |